A team at Kobe University has built a small mirror-image protein that grabs hold of amyloid-beta, the protein at the center of Alzheimer's disease, and stops it from clumping. Writing in Chemistry - A European Journal, biochemical engineer Maruyama Tatsuo and colleagues report that under the conditions they tested, their designed molecule inhibited amyloid-beta more effectively than another drug candidate currently considered promising.
The appeal of the approach lies in the problem it sidesteps. Amyloid-beta is a "disordered" protein, meaning it has no fixed shape, and it is thought to spread that disorder to other proteins until they form the plaques that interfere with brain cell function. Most drug design assumes a well-defined target structure to fit a molecule against. As Maruyama put it, that leaves researchers frustrated when the target is flexible and complex rather than rigid.
The workaround came from materials science. Amino acids, the building blocks of proteins, can exist in two mirror-image forms, like a left and a right hand, though nature almost exclusively uses one. Chemists already knew that short chains of natural "left-handed" and synthetic "right-handed" amino acids can lock together into stable structures, but no one had turned that into a rational design method. Maruyama's group ran a systematic study of small model proteins to work out which molecular features drive efficient binding between the two forms, then applied those rules to build a short right-handed chain tailored to amyloid-beta. The result behaves like a right hand clasping a left one, leaving the captured protein unable to grab anything else.
This is early-stage chemistry rather than a therapy, and the reported advantage over an existing candidate was measured under specific laboratory conditions. What makes it worth watching is the design principle: if mirror-image fragments can be engineered systematically, the same logic could open a route to disordered protein targets that have largely resisted conventional structure-based drug discovery.